FDA approves first mRNA flu vaccine for adults 50 and older

Every autumn, the familiar ritual plays out across America: millions of people roll up their sleeves for a flu shot. The vaccine has become routine enough that its purpose—reducing the risk of severe illness, hospitalization, and death from influenza—can feel almost abstract. This year, that routine has expanded. In August 2026, the Food and Drug Administration approved mFLUSIVA, the first flu vaccine in the United States built on messenger RNA technology, opening a new protection option for adults 50 and older.

The vaccine works by a now-familiar mechanism, though it remains novel in the context of flu prevention. Lipid particles—tiny shells made of fat-like molecules—carry three mRNA sequences into the body's cells. Each sequence contains instructions for producing hemagglutinin, a protein that sits on the surface of the influenza virus. The cells briefly manufacture these proteins, the immune system recognizes them as foreign, and antibodies form in response. When the actual virus arrives, the body's defenses are already primed. The mRNA itself breaks down naturally after delivering its instructions; it does not enter the cell nucleus or alter DNA. The vaccine contains no whole virus and cannot cause influenza.

The technology is not new, though its application to flu is. mRNA has been studied since the 1960s and proven safe and effective in human medicine since the early 2000s. The COVID-19 pandemic demonstrated its potential at scale—mRNA vaccines helped save hundreds of thousands of lives. The same platform is now being tested in melanoma treatment. What makes mFLUSIVA significant is not the technology itself but what it enables: a faster, more flexible response to a virus that changes constantly.

The clinical evidence is straightforward. In a phase three trial involving more than 40,000 adults 50 and older, 2 percent of those who received mFLUSIVA developed flu illness, compared with 2.8 percent of those who received a standard-dose inactivated vaccine. That represents approximately 27 percent lower relative risk. Side effects were mild and familiar—injection site tenderness, fatigue, headache, muscle aches, chills, underarm swelling. About 75 percent of mFLUSIVA recipients reported at least one short-term reaction, compared with 47 percent of those receiving the standard vaccine. Most effects were mild or moderate and resolved within two days.

The scale of the problem mFLUSIVA addresses is substantial. The Centers for Disease Control and Prevention estimates that influenza causes between 120,000 and 710,000 hospitalizations annually in the United States, along with 6,300 to 52,000 deaths. Older adults, people with compromised immune systems, and children face the highest risk. No vaccine prevents every infection, but vaccination reduces transmission and prevents hospitalizations and deaths that would otherwise occur.

For adults 50 to 64, the CDC does not prefer one licensed flu vaccine over another. mFLUSIVA is now one option alongside inactivated and recombinant vaccines, with choice guided by medical history, availability, prior reactions, and personal preference. At 65 and older, the CDC has historically recommended one of three enhanced vaccines: Fluzone High-Dose inactivated vaccine, Flublok recombinant vaccine, or Fluad adjuvanted vaccine. mFLUSIVA is now approved for this age group as well.

The timing of vaccination matters. The CDC recommends vaccination in September or October, because the immune system requires about two weeks to build protection. Vaccinating too early allows that protection to fade before flu season ends. People at higher risk—those 65 and older, pregnant women, people with chronic conditions like asthma or diabetes, those with weakened immune systems, residents of long-term care facilities, and those with a BMI of 40 or higher—should aim for October. Waiting for local case counts to spike is a mistake; surveillance reports lag behind actual transmission.

The real advantage of mRNA technology lies in its adaptability. It is easier to copy viral mRNA sequences than to grow large quantities of influenza virus in a laboratory. That means manufacturers may be able to update seasonal flu vaccines more quickly and respond faster when new strains emerge—a capability that could reshape how the country responds to a virus that has historically required months of preparation and manufacturing. For now, the immediate step is straightforward: anyone eligible should get vaccinated. If mFLUSIVA is not available, any age-appropriate flu vaccine is better than none. The most important action remains the same as it has always been: get vaccinated each year.